1.The Prevalence of Helicobacter pylori Infection in Korean Patients with Inflammatory Bowel Disease, a Multicenter Study.
Min Jun SONG ; Dong Il PARK ; Sang Jun HWANG ; Eun Ran KIM ; Young Ho KIM ; Byeong Ik JANG ; Suck Ho LEE ; Jeong Seon JI ; Sung Jae SHIN
The Korean Journal of Gastroenterology 2009;53(6):341-347
BACKGROUND/AIMS: The prevalence of Helicobacter pylori (H. pylori) infection has been reported to be lower in individuals with inflammatory bowel disease (IBD) in some Western countries. We investigated H. pylori infection in Korean patients with IBD and any possible associations of H. pylori infection with drug therapy for IBD and the phenotype of Crohn's disease (CD). METHODS: We studied 316 unselected patients with IBD, including 169 ulcerative colitis (UC) patients and 147 with CD, and the control group consisted of 316 age- and gender-matched healthy people who received a comprehensive medical examination for a regular checkup purpose. Infection rates of H. pylori as detected by the urea breath test were compared between the IBD patients and the controls. RESULTS: A statistically significant difference in H. pylori infection rate was noticed between the IBD patients (25.3%) and the controls (52.5%; p<0.001), and between UC (32.0%) and CD patients (17.7%; p=0.04). Among the IBD patients, the age group of <60 and individuals with a history of taking metronidazole (13.0%; p=0.038) or ciprofloxacin (6.7%; p=0.001) were found to have a meaningfully lower infection rate, but those who did not take antibiotics still showed H. pylori infection rate significantly lower than the controls (CD 22.0% vs. UC 33.8% vs. Control 52.5%, p<0.001). With an exception of age, phenotypic characteristics showed no significant relations with H. pylori infection rate in CD patients. CONCLUSIONS: Korean patients with IBD, particularly CD, were found to have a significantly lower H. pylori infection rate than the controls. This association was more evident in those <60 years old, which suggested that H. pylori infection might be deemed to lower possible risks of IBD in younger adults.
Adolescent
;
Adult
;
Age Factors
;
Aged
;
Colitis, Ulcerative/complications/diagnosis/drug therapy
;
Crohn Disease/complications/diagnosis/drug therapy
;
Female
;
Helicobacter Infections/complications/diagnosis/*epidemiology
;
*Helicobacter pylori
;
Humans
;
Inflammatory Bowel Diseases/*complications/diagnosis/drug therapy
;
Korea
;
Male
;
Middle Aged
;
Phenotype
;
Prevalence
2.Paediatric inflammatory bowel disease in a multiracial Asian country.
Hui Ping CHU ; Veena LOGARAJAH ; Nancy TAN ; Kong Boo PHUA
Singapore medical journal 2013;54(4):201-205
INTRODUCTIONThis study examined the characteristics and trends in the incidence of inflammatory bowel disease (IBD) among children in Singapore.
METHODSWe retrospectively reviewed all patients under 18 years diagnosed with IBD over a 14-year period. Information on demographics, disease presentation, laboratory findings, radiological investigations, and endoscopic and histological findings were obtained from the patients' medical records.
RESULTS32 patients were diagnosed with IBD, 30 of whom had Crohn's disease and 2 had ulcerative colitis. The incidence of IBD rose from an initial rate of 2.2 per 100,000 patients in the year 2000 to a peak of 11.4 patients per 100,000 patients by 2008. Median age of onset of symptoms was 10.5 years. There were more boys (63%) than girls in the group and a higher representation of Indians (34.4%). The most common presenting symptoms were abdominal pain (87.5%), diarrhoea (75.0%) and weight loss (71.9%). Extraintestinal manifestations such as fever and arthralgia were found in over 50% of patients. The most common physical findings were perianal abnormalities (56.3%), mouth ulcers (37.5%) and growth failure (15.6%). Abnormal laboratory findings such as low albumin, raised erythrocyte sedimentation rate, anaemia, thrombocytosis and high C-reactive protein were found in nearly half of the patients. Endoscopic and histological findings showed that a majority of patients (90.6%) also had evidence of inflammation in the upper gastrointestinal tract.
CONCLUSIONPaediatric IBD is on the rise. The higher occurrence in Indians, earlier onset and more florid presentation may suggest different genetic and environmental influences specific to Asian children.
Adolescent ; Age of Onset ; Child ; Child, Preschool ; Colitis, Ulcerative ; diagnosis ; Crohn Disease ; diagnosis ; Environment ; Ethnic Groups ; Female ; Genetic Predisposition to Disease ; Humans ; Inflammation ; Inflammatory Bowel Diseases ; diagnosis ; epidemiology ; ethnology ; therapy ; Male ; Retrospective Studies ; Singapore ; epidemiology ; Treatment Outcome
3.The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-alpha Blockers.
Ja Min BYUN ; Chang Kyun LEE ; Sang Youl RHEE ; Hyo Jong KIM ; Jung Wook KIM ; Jae Jun SHIM ; Jae Young JANG
Journal of Korean Medical Science 2015;30(2):173-179
The aims of this study were to assess the risk of tuberculosis (TB) and the status of latent tuberculosis infection (LTBI) in Korean patients with inflammatory bowel disease (IBD) receiving tumor necrosis factor (TNF)-alpha blockers. We reviewed medical records of 525 Korean IBD patients (365 TNF-alpha blocker naive and 160 TNF-alpha blocker exposed) between January 2001 and December 2013. The crude incidence of TB was significantly higher in IBD patients receiving TNF-alpha blockers compared to TNF-alpha-blocker-naive patients (3.1% vs. 0.3%, P=0.011). The mean incidence of TB per 1,000 patient-years was 1.84 for the overall IBD population, 4.89 for TNF-alpha blocker users, and 0.45 for TNF-alpha-blocker-naive patients. The adjusted risk ratio of TB in IBD patients receiving TNF-alpha blocker was 11.7 (95% confidence interval, 1.36-101.3). Pulmonary TB was prevalent in patients treated with TNF-alpha blockers (80.0%, 4/5). LTBI was diagnosed in 17 (10.6%) patients, and none of the 17 LTBI patients experienced reactivation of TB during treatment with TNF-alpha blockers. Treatment with TNF-alpha blockers significantly increased the risk of TB in IBD patients in Korea. De novo pulmonary TB infection was more prevalent than reactivation of LTBI, suggesting an urgent need for specific recommendations regarding TB monitoring during TNF-alpha blocker therapy.
6-Mercaptopurine/adverse effects/analogs & derivatives/therapeutic use
;
Adult
;
Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
;
Antibodies, Monoclonal/adverse effects/therapeutic use
;
Cohort Studies
;
Colitis, Ulcerative/*drug therapy
;
Crohn Disease/*drug therapy
;
Female
;
Humans
;
Latent Tuberculosis/chemically induced/diagnosis/*epidemiology
;
Male
;
Mycobacterium tuberculosis/isolation & purification
;
Republic of Korea
;
Retrospective Studies
;
Tuberculosis, Pulmonary/chemically induced/diagnosis/*epidemiology
;
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
4.The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-alpha Blockers.
Ja Min BYUN ; Chang Kyun LEE ; Sang Youl RHEE ; Hyo Jong KIM ; Jung Wook KIM ; Jae Jun SHIM ; Jae Young JANG
Journal of Korean Medical Science 2015;30(2):173-179
The aims of this study were to assess the risk of tuberculosis (TB) and the status of latent tuberculosis infection (LTBI) in Korean patients with inflammatory bowel disease (IBD) receiving tumor necrosis factor (TNF)-alpha blockers. We reviewed medical records of 525 Korean IBD patients (365 TNF-alpha blocker naive and 160 TNF-alpha blocker exposed) between January 2001 and December 2013. The crude incidence of TB was significantly higher in IBD patients receiving TNF-alpha blockers compared to TNF-alpha-blocker-naive patients (3.1% vs. 0.3%, P=0.011). The mean incidence of TB per 1,000 patient-years was 1.84 for the overall IBD population, 4.89 for TNF-alpha blocker users, and 0.45 for TNF-alpha-blocker-naive patients. The adjusted risk ratio of TB in IBD patients receiving TNF-alpha blocker was 11.7 (95% confidence interval, 1.36-101.3). Pulmonary TB was prevalent in patients treated with TNF-alpha blockers (80.0%, 4/5). LTBI was diagnosed in 17 (10.6%) patients, and none of the 17 LTBI patients experienced reactivation of TB during treatment with TNF-alpha blockers. Treatment with TNF-alpha blockers significantly increased the risk of TB in IBD patients in Korea. De novo pulmonary TB infection was more prevalent than reactivation of LTBI, suggesting an urgent need for specific recommendations regarding TB monitoring during TNF-alpha blocker therapy.
6-Mercaptopurine/adverse effects/analogs & derivatives/therapeutic use
;
Adult
;
Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
;
Antibodies, Monoclonal/adverse effects/therapeutic use
;
Cohort Studies
;
Colitis, Ulcerative/*drug therapy
;
Crohn Disease/*drug therapy
;
Female
;
Humans
;
Latent Tuberculosis/chemically induced/diagnosis/*epidemiology
;
Male
;
Mycobacterium tuberculosis/isolation & purification
;
Republic of Korea
;
Retrospective Studies
;
Tuberculosis, Pulmonary/chemically induced/diagnosis/*epidemiology
;
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
5.Relapse Rates of Ulcerative Colitis in Remission and Factors Related to Relapse.
Byoung Joon PARK ; Kwang Jae LEE ; Jae Chul HWANG ; Sung Jae SIN ; Jae Yeon CHUNG ; Sung Won CHO
The Korean Journal of Gastroenterology 2008;52(1):21-26
BACKGROUND/AIMS: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with heterogeneous clinical features. Data on the disease course and prognosis of UC patients who have been regularly treated are lacking. We aimed to investigate relapse rates of UC in remission and factors related to relapse. METHODS: We retrospectively analyzed clinical courses of 84 patients (43 males, median age 43 years, ranged 20-73 years) diagnosed as UC at Ajou University Hospital between January 1997 and December 2005 based on clinical, endoscopic and pathologic findings, and who were regularly followed for at least one year after the remission. RESULTS: Study subjects consisted of 32 proctitis (38%), 21 left-sided colitis (25%), and 31 subtotal or total colitis (37%). Of 84 patients, relapse was observed in 52 patients (62%) during the follow-up period (ranged 1-9 years). The relapse rate was 24%, 41%, 51%, 65%, 71%, and 79% at 1 year, 2 years, 3 years, 4 years, 5 years and 6 years, respectively. Among sex, age, hemoglobin, ESR, and the extent of disease on admission, decrease of hemoglobin level was the only independent factor related to relapse (odds ratio=2.67, 95% CI (1.32-5.42), p<0.01). CONCLUSIONS: In Korea, relapse of UC in remission is not rare. Decrease of hemoglobin level is an independent risk factor related to its relapse, while the extent of disease is not.
Adult
;
Aged
;
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
;
Antimetabolites/therapeutic use
;
Azathioprine/therapeutic use
;
Chronic Disease
;
Colitis, Ulcerative/*diagnosis/*epidemiology/therapy
;
Data Interpretation, Statistical
;
Female
;
Follow-Up Studies
;
Hemoglobins/analysis
;
Humans
;
Male
;
Mesalamine/therapeutic use
;
Middle Aged
;
Odds Ratio
;
Recurrence
;
Retrospective Studies
;
Risk Factors
;
Time Factors